Landos Biopharma Inc

NASDAQ:LABP   1:35:24 PM EDT
0.24
-0.01 (-4.82%)
Earnings Announcements

Landos Biopharma Reports Third Quarter Results

Published: 11/10/2022 13:24 GMT
Landos Biopharma Inc (LABP) - Landos Biopharma Reports Third Quarter 2022 Results and Provides Business Update.
Landos Biopharma Inc - As of September 30, Had Cash, Cash Equivalents, Marketable Securities of $48.0 Million.
Landos Biopharma Inc - Cash, Cash Equivalents, Marketable Securities Will Be Sufficient to Fund Planned Operations for at Least Next 12 Months.
Landos Biopharma Inc - Qtrly Loss per Share $0.20.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.21

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.29

More details on our Analysts Page.